B.B.B

Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study

Retrieved on: 
Tuesday, March 5, 2024
Regeneration, Regulation, LPT, Person, Blood, Pathology, News, Cannabidiol, Animal, Dog, Schizophrenia, Sheep, Stroke, Goat, Indian stock exchange, Unit, Pharmacokinetics, Rabbit, DSM-IV codes, Spectrum, B.B.B, Mouse, Brain, Medical imaging

HERZLIYA, Israel and CALGARY, Alberta, March 5, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the following:

Key Points: 
  • In the Company's latest study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them.
  • These results show a strong correlation between the prolonged blood exposure of CBD and its brain distribution.
  • Sufficient exposure of CBD in the brain is the hallmark of CBD therapy associated with various neurological conditions.
  • The fact that LPT-CBD successively delivers CBD to the brain in a long-lasting manner opens a big venue for the treatment of various neurological disorders.